更新于：2024-12-10
Hydrocortisone Acetate
醋酸氢化可的松
更新于：2024-12-10
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C23H32O6 |
InChIKeyALEXXDVDDISNDU-JZYPGELDSA-N |
CAS号50-03-3 |
关联
16
项与 醋酸氢化可的松 相关的临床试验A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone in Management of Atopic Dermatitis in Children
3-Arm Randomized Placebo Controlled Double Blind Phase 3 Study to Evaluate Safety and Efficacy of Once-Daily and Twice-Daily Hydrocortisone Acetate 90 mg Suppository Administered With a Sephure Applicator in Subjects With Ulcerative Colitis
Effects of Vitamin C, Thiamine and Hydrocortisone in Septic Shock: a Randomized, Controlled Trial
100 项与 醋酸氢化可的松 相关的临床结果
登录后查看更多信息
100 项与 醋酸氢化可的松 相关的转化医学
登录后查看更多信息
100 项与 醋酸氢化可的松 相关的专利（医药）
登录后查看更多信息
2,057
项与 醋酸氢化可的松 相关的文献（医药）2024-08-28Cureus Journal of Medical Science
Successful Management of Pyoderma Gangrenosum in a Patient With Concurrent Behçet’s Disease and Familial Mediterranean Fever: A Case Report
Article
作者: Al Irr, Nael ; Helou, Maroun
Pyoderma gangrenosum (PG) is a rare ulcerative skin condition. Familial Mediterranean fever (FMF) and Behçet's disease (BD) are autoinflammatory disorders common in Mediterranean populations. The coexistence of FMF and BD is unusual, and the presence of PG alongside both is even rarer. We present a case of a 51-year-old male diagnosed with both BD and FMF who developed PG during treatment. His PG lesion was managed with a tailored regimen that included topical hydrocortisone acetate with fusidic acid, colchicine, topical tacrolimus, oral prednisone, and intravenous infliximab, which led to the successful healing of the PG lesion. This case underscores the need for specialized approaches to manage overlapping autoinflammatory conditions.
2024-08-01Inflammation
Three Main SCFAs Mitigate Lung Inflammation and Tissue Remodeling Nlrp3-Dependent in Murine HDM-Induced Neutrophilic Asthma
Article
作者: Keller, Alexandre C ; Bortoluci, Karina R ; Vieira, Rodolfo P ; Gonzatti, Michelangelo B ; Tagé, Barbara S S ; Aimbire, Flávio
Neutrophilic asthma is generally defined by poorly controlled symptoms and high levels of neutrophils in the lungs. Short-chain fatty acids (SCFAs) are proposed as nonpharmacological therapy for allergic asthma, but their impact on the neutrophilic asthma lacks evidence. SCFAs regulate immune cell responses and impact the inflammasome NLRP3, a potential pharmacological target for neutrophilic asthma. Here, we explored the capacity of SCFAs to mitigate murine-induced neutrophilic asthma and the contribution of NLRP3 to this asthma. The objective of this study is to analyze whether SCFAs can attenuate lung inflammation and tissue remodeling in murine neutrophilic asthma and NLRP3 contribution to this endotype. Wild-type (WT) C57BL6 mice orotracheally received 10 μg of HDM (house dust mite) in 80 μL of saline on days 0, 6-10. To explore SCFAs, each HDM group received 200 mM acetate, propionate, or butyrate. To explore NLRP3, Nlrp3 KO mice received the same protocol of HDM. On the 14th day, after euthanasia, bronchoalveolar lavage fluid (BALF) and lungs were collected to evaluate cellularity, inflammatory cytokines, and tissue remodeling. HDM group had increased BALF neutrophil influx, TNF-α, IFN-γ, IL-17A, collagen deposition, and mucus secretion compared to control. SCFAs distinctively attenuate lung inflammation. Only features of tissue remodeling were Nlrp3-dependent such as collagen deposition, mucus secretion, active TGF-β cytokine, and IMs CD206+. SCFAs greatly decreased inflammatory cytokines and tissue remodeling. Only tissue remodeling was dependent on NLRP3. It reveals the potential of SCFAs to act as an additional therapy to mitigate neutrophilic asthma and the NLRP3 contribution to asthma.
2024-07-01Phytomedicine : international journal of phytotherapy and phytopharmacology
In vitro pharmacokinetic behavior in lung of harringtonine, an antagonist of SARS-CoV-2 associated proteins: New insights of inhalation therapy for COVID-19
Article
作者: Ma, Xiaoyu ; Zhang, Yuxiu ; Lei, Panpan ; Ma, Weina ; Su, Xinyue ; Ren, Bingxi ; Zhang, Yongjing ; Liang, Jinna ; Gao, Jiapan
BACKGROUND:
Recent studies have shown that harringtonine (HT) could specifically bind with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein and host cell transmembrane serine protease 2 (TMPRSS2) to block membrane fusion, which is an effective antagonist for SARS-CoV-2.
PURPOSE:
Our study focused on in-depth exploration of in vitro pharmacokinetic characteristics of HT in lung.
METHODS:
HPLC-fluorescence detection method was used to detect changes of HT content. Incubation systems of lung microsomes for phase I metabolism and UGT incubation systems for phase II metabolism were performed to elucidate metabolites and metabolic mechanisms of HT, and then the metabolic enzyme phenotypes for HT were clarified by chemical inhibition method and recombinant enzyme method. Through metabolomics, we comprehensively evaluated the physiological dynamic changes in SD rat and human lung microsomes, and revealed the relationship between metabolomics and pharmacological activity of HT.
RESULTS:
HPLC-fluorescence detection method showed strong specificity, high accuracy, and good stability for rapid quantification of HT. We confirmed that HT mainly underwent phase I metabolism, and the metabolites of HT in different species were all identified as 4'-demethyl HT, with metabolic pathway being hydrolysis reaction. CYP1A2 and CYP2E1 participated in HT metabolism, but as HT metabolism was not NADPH dependent, the esterase HCES1 in lung also played a role. The main KEGG pathways in SD rat and human lung microsomes were cortisol synthesis and secretion, steroid hormone biosynthesis and linoleic acid metabolism, respectively. The downregulated key biomarkers of 11-deoxycortisol, 21-deoxycortisol and 9(10)-EpOME suggested that HT could prevent immunosuppression and interfere with infection and replication of SARS-CoV-2.
CONCLUSION:
HT was mainly metabolized into 4'-demethyl HT through phase I reactions, which was mediated by CYP1A2, CYP2E1, and HCES1. The downregulation of 11-deoxycortisol, 21-deoxycortisol and 9(10)-EpOME were key ways of HT against SARS-CoV-2. Our study was of great significance for development and clinical application of HT in the treatment of COVID-19.
100 项与 醋酸氢化可的松 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 皮炎 | 澳大利亚 | 1991-10-14 | |
| 湿疹 | 澳大利亚 | 1991-10-14 | |
| 溃疡性直肠炎 | 美国 | 1982-02-10 | |
| 溃疡性结肠炎 | 美国 | 1951-12-21 | |
| 皮肤疾病 | 美国 | 1951-12-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 103 | (Hydrocortisone Acetate Suppository, 25 mg) | 願觸膚製鏇積鬱膚簾鹽(壓糧醖獵構窪構壓衊憲) = 壓選齋夢蓋範餘膚遞構 壓繭憲獵齋醖壓顧繭艱 (壓艱範獵鏇顧製糧夢鑰, 鬱餘鹽艱淵鹽鏇構遞襯 ~ 壓鬱淵膚獵鹹壓遞鏇鏇) 更多 | - | 2022-09-13 | ||
Placebo (Vehicle) Suppository (Nivagen) (Placebo (Vehicle) Suppository) | 願觸膚製鏇積鬱膚簾鹽(壓糧醖獵構窪構壓衊憲) = 製鏇艱壓獵觸淵顧網獵 壓繭憲獵齋醖壓顧繭艱 (壓艱範獵鏇顧製糧夢鑰, 築製衊構獵鏇鑰簾構築 ~ 願築夢範鬱糧夢觸製夢) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用